Profile data is unavailable for this security.
About the company
Akari Therapeutics, Plc is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. The Company is engaged in the development of antibody drug conjugates (ADCs) and advanced therapies for autoimmune and inflammatory diseases, including geographic atrophy (GA). Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. The Company is conducting pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA). It is conducting a phase III clinical trial in pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The Company's pipeline also includes the PH-1 ADC Platform for oncology, PHP-303 program for genetic disease, liver disease and inflammation, specifically for Alpha-1 antitrypsin deficiency (AATD) and acute respiratory distress syndrome (ARDS), including COVID-19.
- Revenue in USD (TTM)0.00
- Net income in USD-20.13m
- Incorporated2004
- Employees9.00
- LocationAkari Therapeutics PLC22 BOSTON WHARF ROAD, FL 7BOSTON 02210United StatesUSA
- Phone+1 (646) 350-0702
- Fax+1 (646) 843-9352
- Websitehttps://www.akaritx.com/
More ▼
Mergers & acquisitions
| Acquired company | AKTX:NAQ since announced | Transaction value |
|---|---|---|
| Peak Bio Inc | -44.89% | -- |
Data delayed at least 15 minutes, as of Nov 21 2024 19:27 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Natural Alternatives International, Inc. | 112.98m | -8.50m | 27.40m | 296.00 | -- | 0.3417 | -- | 0.2425 | -1.45 | -1.45 | 19.19 | 12.94 | 0.7028 | 4.35 | 8.25 | 381,679.10 | -5.29 | 2.33 | -6.04 | 2.80 | 5.30 | 14.24 | -7.53 | 2.06 | 1.50 | -9.35 | 0.1536 | 0.00 | -26.11 | -3.82 | -386.16 | -- | -10.75 | -- |
| Dare Bioscience Inc | 1.88m | -3.60m | 27.65m | 23.00 | -- | -- | -- | 14.69 | -0.5276 | -0.5276 | 0.2303 | -0.1737 | 0.0873 | -- | 2.28 | 81,796.52 | -16.72 | -109.51 | -199.47 | -246.26 | 3.50 | -- | -191.61 | -1,104.55 | -- | -- | -- | -- | -71.92 | -- | 2.54 | -- | 121.37 | -- |
| KALA BIO Inc | 0.00 | -38.96m | 29.63m | 43.00 | -- | 4.32 | -- | -- | -12.47 | -12.47 | 0.00 | 1.49 | 0.00 | -- | -- | 0.00 | -67.64 | -57.83 | -96.17 | -69.32 | -- | 57.06 | -- | -1,553.61 | -- | -11.21 | 0.8367 | -- | -100.00 | -- | 5.85 | -- | -17.31 | -- |
| Opus Genetics Inc | 8.38m | -27.19m | 30.81m | 14.00 | -- | 0.7485 | -- | 3.68 | -1.09 | -1.09 | 0.3369 | 1.31 | 0.1772 | -- | 1.14 | 598,642.90 | -57.50 | -58.31 | -64.30 | -65.94 | -- | -- | -324.45 | -137.92 | -- | -- | 0.00 | -- | -52.20 | -- | -155.83 | -- | -- | -- |
| ImmuCell Corp | 23.84m | -3.81m | 32.08m | 74.00 | -- | 1.20 | -- | 1.35 | -0.4856 | -0.4856 | 3.03 | 2.99 | 0.5357 | 2.35 | 11.43 | 301,746.80 | -8.56 | -5.16 | -9.39 | -5.53 | 26.71 | 40.04 | -15.99 | -12.64 | 1.44 | -6.21 | 0.2922 | -- | -5.90 | 9.72 | -131.56 | -- | -1.39 | -- |
| Tonix Pharmaceuticals Holding Corp | 11.29m | -135.25m | 35.51m | 103.00 | -- | 0.3985 | -- | 3.14 | -52.81 | -52.81 | 0.6477 | 0.4768 | 0.0964 | 0.8291 | 4.05 | 109,621.40 | -115.46 | -59.46 | -134.34 | -65.92 | 20.74 | -- | -1,197.86 | -5,126.73 | 2.78 | -- | 0.0972 | -- | -- | -- | 0.1874 | -- | 320.57 | -- |
| Akari Therapeutics PLC (ADR) | 0.00 | -20.13m | 36.40m | 9.00 | -- | -- | -- | -- | -2.98 | -2.98 | 0.00 | -0.3049 | 0.00 | -- | -- | 0.00 | -307.64 | -149.95 | -- | -435.18 | -- | -- | -- | -- | -- | -378.19 | -- | -- | -- | -- | 43.61 | -- | -- | -- |
| Incannex Healthcare Inc | 86.00k | -23.15m | 36.87m | 9.00 | -- | 5.59 | -- | 428.76 | -1.40 | -1.40 | 0.0052 | 0.3738 | -- | -- | -- | 9,555.56 | -- | -130.12 | -- | -148.24 | -- | -- | -26,922.09 | -3,421.98 | -- | -- | 0.00 | -- | -- | 61.03 | 62.18 | -- | 73.79 | -- |
| Lexaria Bioscience Corp | 411.01k | -4.85m | 38.40m | 5.00 | -- | 3.44 | -- | 93.42 | -0.4455 | -0.4455 | 0.0408 | 0.6403 | 0.0539 | -- | 2.16 | 82,202.00 | -63.85 | -95.67 | -65.93 | -96.58 | 98.83 | 76.98 | -1,185.15 | -1,612.76 | -- | -64.96 | 0.00 | -- | -11.43 | -12.19 | 8.31 | -- | -- | -- |
| CEL-SCI Corp | 0.00 | -29.10m | 38.62m | 43.00 | -- | 4.02 | -- | -- | -0.5806 | -0.5806 | 0.00 | 0.1562 | 0.00 | -- | -- | -- | -100.88 | -70.19 | -124.78 | -78.31 | -- | -- | -- | -15,434.15 | 0.1793 | -36.79 | 0.5517 | -- | -- | -- | 13.99 | -- | 223.59 | -- |
| Verrica Pharmaceuticals Inc | 9.21m | -84.99m | 40.47m | 100.00 | -- | -- | -- | 4.39 | -1.83 | -1.83 | 0.1979 | -0.7467 | 0.1416 | 1.67 | 4.67 | 92,100.00 | -130.68 | -55.75 | -174.03 | -78.33 | 74.08 | -- | -922.81 | -754.94 | 1.22 | -10.16 | 3.82 | -- | -43.27 | -- | -173.59 | -- | 5.65 | -- |
| Fortress Biotech Inc | 62.50m | -57.53m | 43.27m | 186.00 | -- | 2.05 | -- | 0.6924 | -3.53 | -3.53 | 3.74 | 0.767 | 0.4502 | 2.16 | 6.70 | 336,026.90 | -88.98 | -52.50 | -142.15 | -99.46 | 60.55 | 63.17 | -197.64 | -236.94 | 1.06 | -9.66 | 1.31 | -- | 11.58 | 25.75 | 27.42 | -- | -9.37 | -- |
| United-Guardian, Inc. | 12.31m | 3.48m | 44.61m | 25.00 | 12.80 | 3.92 | 12.44 | 3.62 | 0.7585 | 0.7585 | 2.68 | 2.48 | 0.9684 | 4.74 | 7.44 | 492,490.80 | 27.41 | 29.84 | 31.57 | 34.39 | 53.43 | 55.31 | 28.30 | 28.79 | 6.02 | -- | 0.00 | 97.37 | -14.28 | -4.14 | 0.4616 | -9.92 | 17.19 | -19.73 |
| SCYNEXIS Inc | 8.57m | -36.44m | 44.78m | 29.00 | -- | 0.765 | -- | 5.23 | -0.756 | -0.756 | 0.177 | 1.54 | 0.0692 | -- | 3.61 | 295,379.30 | -29.44 | -30.02 | -35.54 | -36.35 | -71.42 | -- | -425.41 | -86.76 | -- | -- | 0.1843 | -- | 2,652.72 | 252.64 | 206.74 | -- | -- | -- |
Data as of Nov 21 2024. Currency figures normalised to Akari Therapeutics PLC's reporting currency: US Dollar USD
1.49%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Omnia Family Wealth LLCas of 30 Sep 2024 | 87.63k | 0.72% |
| Citadel Securities LLCas of 30 Sep 2024 | 33.26k | 0.27% |
| Cerity Partners LLCas of 30 Sep 2024 | 23.64k | 0.20% |
| Cresset Asset Management LLCas of 30 Sep 2024 | 18.41k | 0.15% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 18.07k | 0.15% |
| Bank of America, NA (Private Banking)as of 30 Sep 2024 | 150.00 | 0.00% |
| Osaic Fa, Inc. (Investment Management)as of 30 Sep 2024 | 100.00 | 0.00% |
| Truvestments Capital LLCas of 30 Sep 2024 | 50.00 | 0.00% |
| BG Fund Management Luxembourg SAas of 30 Jun 2024 | 14.00 | 0.00% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2024 | 8.00 | 0.00% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
